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An Artificial Cofactor Catalyzing the Baylis-Hillman
Reaction with Designed Streptavidin as Protein Host**
Horst Lechner,*[a] Vincent R. Emann,[a] M. Breuning,[b] and Birte Höcker*[a]
An artificial cofactor based on an organocatalyst embedded in a
protein has been used to conduct the Baylis-Hillman reaction in
a buffered system. As protein host, we chose streptavidin, as it
can be easily crystallized and thereby supports the design
process. The protein host around the cofactor was rationally
designed on the basis of high-resolution crystal structures
obtained after each variation of the amino acid sequence.
Additionally, DFT-calculated intermediates and transition states
were used to rationalize the observed activity. Finally, repeated
cycles of structure determination and redesign led to a system
with an up to one order of magnitude increase in activity over
the bare cofactor and to the most active proteinogenic catalyst
for the Baylis-Hillman reaction known today.
The design of proteins that display new catalytic activities is still
a major challenge. Although several successful examples were
reported,[1–3] these de novo cases are limited to a small set of
reactions, such as the Kemp elimination,[4,5] the retro-aldol
reaction,[6] and a bimolecular Diels-Alder reaction.[7] All the initial
designs provided a sufficient starting point (kcat 0.17) but had to
be strongly improved through directed evolution to show
reasonable rate enhancement.[8–10]
Half of all natural enzyme catalyzed reactions require
cofactor(s) as part of their catalytic machinery.[11] Therefore, it is
not surprising that far more new protein-based catalysts were
reported using artificial (metal-based) cofactors embedded in
host-proteins.[12–16] These cofactors bear the advantage of
intrinsic activity, which is usually low without a surrounding
protein. The protein can provide a different environment for
the catalysis – in most cases increasing the activity and maybe
even facilitating (stereo)selective reactions.
There are several examples using streptavidin as the host
for these cofactors, since its natural ligand biotin binds strongly
(Kd ~ 10
  15 M) and is easy to modify with catalysts at the
carboxylic acid group. The location of the catalyst is in a shallow
cavity at the surface of the protein. Streptavidin is a known
thermo- and solvent stable protein, which is another advantage
in the development of new catalysts. Contrary to metal-based
cofactors, organocatalysts are rarely used in this context. There
are only few examples: proline[17] and an imidazolium salt[18]
were applied in wild-type (wt)-streptavidin as host for Michael
additions and Aldol reactions, respectively. Additionally there
are examples for organocatalysts embedded into proteins via
noncanonical amino acids.[19,20]
No enzyme is known to naturally catalyze the Baylis-Hillman
reaction,[21,22] a very versatile and atom-economic C  C bond
forming reaction for the production of various functionalized
compounds[23] and intermediates of active pharmaceutical
ingredients (APIs).[24] There were attempts to design a de novo
enzyme but with only minor success, leading to 24 % yield
using 38 Mol% catalyst (BH32 N14I) after 28 hours.[25] Never-
theless, it was recognized that this reaction can be catalyzed
using nucleophilic amine catalysts in aqueous systems,
although with low rates and high catalyst concentrations. (Imid)
azoles,[26,27] DABCO,[28,29] 3-hydroxyquinuclidine[29] and 4-dimeth-
ylaminopyridine (DMAP)[29] were reported as catalysts for this
purpose. We describe here the use of an artificial cofactor
employing the well-known biotin-streptavidin system to cata-
lyze a Baylis-Hillman reaction.
We chose a derivative of DMAP as the artificial cofactor due
to its low steric demand, which will facilitate its inclusion into
the protein scaffold. Starting from 4-(4-aminopiperidino)
pyridine we successfully synthesized the artificial cofactor 4
(Figure 1B).
A streptavidin variant (PDB ID: 5F2B),[30] named here wt
streptavidin, was used as the protein host due to its aforemen-
tioned advantages. The protein was expressed, purified and,
after adding 4, its activity tested in the Baylis-Hillman model
reaction with p-nitrobenzaldehyde 1 and cyclopentenone 2 as
the substrates (Figure 1A). No activity above the background
activity as catalyzed by streptavidin itself (Table 1, entries 4 and
5) could be detected. To reveal the reason why there was no
catalytic activity, the protein was crystallized and the X-ray
structure was solved (Figure 1C, PDB ID: 6T1E). It clearly
visualized that 4 is placed nicely at the entrance of the biotin-
binding pocket. The density of the ligand is very well resolved
(see Composite Omit maps, Figure S1 in the Supporting
Information). As depicted in Figures 1C and 2A, the active site
of the catalyst is sterically hindered by the side chains of Q114
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and R121 and its position will be mainly affected by S112 at the
bottom of the pyridine part. Especially position 121 is known to
influence the outcome of metal-based catalysts to a great
extent.[31] Thus, to reduce the steric hindrance at the catalytic
site, bulky Q114 was changed to A or T, and R121 and S112
were substituted by A as well to create space at the active site,
and to position the catalyst as deeply as possible in this cleft.
Additionally, the variant S112A, R121A was tested, but none of
these variants showed activity higher than the background.
Exemplarily the activity of streptavidin S112A Q114A R121A is
shown in Table 1, entry 6. The derived crystal structures of these
variants revealed that 4 was now shifted to a position close to
the amide carbonyl oxygen of A121, leading to an inaccessible
nucleophilic nitrogen atom (Figure 2B yellow). An attempt of
introducing Y as a bulkier amino acid at position L124 behind
the catalyst to push the DMAP nitrogen atom forward was not
successful either (Figure 2B pink). In a next step we varied S112
beneath the catalyst. By increasing its size from A to its original
S and further increasing this residue to M, F and I, we reasoned
it might force the catalyst into a more productive position. The
variant harboring S112, however, led to no activity and a similar
structure was obtained (PDB ID: 6T30) as in round 1 and 2 of
our design approaches. But in contrast, all variants harboring
sterically more demanding residues at position 112 (I, F, M)
displayed activity (Table 1, entries 7–11 and Table S7, entries 4–
15). Our reasoning was supported by the X-ray structures of
these variants (Figure 2C) where the position of the nucleophilic
nitrogen of 4 superimposes with the one from the initial
structure. The S112I variant displayed the highest activity
among the three variants (Table 1, entry 9). The S112F variant,
although structurally very similar to S112I (Figure 2C), reached
roughly half of the yield as the S112I variant (Table 1, entry 10).
Reasons for this might be π-π interactions of F112 and the
catalyst. S112M (PDB ID: 6T2Z) led to two different conforma-
tions of 4 (Figure S1) and very low activities (Table 1, entry 11).
While all these constructs are active, they however lack
enantioselectivity.
Two major questions arise with these results in hand: What
is the cause for the “background” reaction displayed by
streptavidin alone? And why does the active protein-cofactor
system lack enantioselectivity?
We want to address the question regarding the high
background first. In this context it is worth mentioning that
others[32] reported some proteins at high concentrations
(30 mg/mL), such as the carrier protein BSA, being able to
catalyze the Baylis-Hillman reaction. However, the mechanism
of catalysis was not elucidated further.
We considered histidine residues at the surface of streptavi-
din as additional, unwanted active sites, since it was described
that (imid)azoles[26,33] can serve as catalysts under certain
conditions. Streptavidin has two histidine residues per mono-
mer located at the surface (H87, H127; Figure S2). Both were
predicted to have a pKa�7 (SI), while the ones of all lysines are
predicted above 9.8 (Table S4). As H127 is known to be tolerant
against mutations,[34] we created a double mutant of the S112I
variant with a H127Q and K49N exchange. The latter exchange
removed a lysine close to the catalyst, which could also
influence the outcome of the reaction.
The yields of the background reaction dropped a bit, but
remained in a similar range (Table 1, entry 12 and Table S7,
entry 10). Thus, H127 has minor importance for the background
reaction. The yields of the reaction with cofactor (Table 1,
entry 13 and Table S7, entry 11), reveal, that K49 influences
activity as the yield dropped slightly.
Figure 1. Concept of the artificial cofactor-protein host system. A) model
reaction: DMAP-catalyzed Baylis-Hillman reaction between enone 1 and
aldehyde 2 providing racemic alcohol 3. B) Artificial cofactor 4 consisting of
a biotinylated DMAP derivative. C) Crystal structure of the tetrameric wt
streptavidin harboring 4 and a closeup of the binding site of 4.
Table 1. Activities and selectivities of catalysts and selected streptavidin









1 – – 48 0
2 DMAP 2 24 3
3 4 2 24 1
4 wt streptavidin[b] 1 24 6
5 wt streptavidin 2 48 11 <5
6 S112A Q114A R121A[b] +4 1 24 8
7 S112I Q114A R121A L124Y[b] -
+4
1 24 13
8 S112I Q114A R121A L124Y+4 2 24 16
9 S112I Q114A R121A L124Y+4 2 48 35 <5
10 S112F Q114A R121A L124Y
+4
2 48 17 <5
11 S112M Q114A R121A L124Y
+4
2 48 12 <5
12 K49N S112I Q114A R121A
L124Y H127Q[b]
1 48 5
13 K49N S112I Q114A R121A
L124Y H127Q[b]+ 4
1 48 14
Reaction conditions: HEPES buffer (10 mM, pH 7.0), streptavidin (2.6 mol %
of monomer), DMSO (20 vol%), 4-nitrobenzaldehyde (1, 50 mM), cyclo-
pentenone (2, 100 mM), 30 °C, orbital shaking 1000 rpm. [a] Determined by
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Exchange of H87 was already recognized to disturb the
integrity of the protein.[35] After careful inspection of the
structures we suspect that this histidine forms a hydrogen bond
to an aspartic acid (D61) of an adjacent protein chain keeping
loops of neighboring subunits of streptavidin together and
creating a “catalytic diad” by activating the histidine, which
would explain the outcome of our experiments. Our efforts to
change this H87 to a D, N or S unfortunately led to unfolded
protein, only the double mutant H87Y and D61I could be
refolded with very low yields and diminished biotin binding
ability.
As a consequence, this variant could not be characterized
further. Next, we addressed the issue of enantioselectivity.
Increasing the size of the aldehyde by using Isatin[36] or even
bulkier N-methyl-isatin instead of nitrobenzaldehyde 1 with the
aim to achieve stereoselectivity via “substrate engineering” led
to yields of up to 87 %, but also in these cases no noticeable
enantioselectivity was detected (Table S4). Firstly, the lack of
stereocontrol was investigated more deeply using DFT meth-
ods. We employed ORCA[37] to calculate a simplified reaction
pathway until I2 using a truncated cofactor 5 (SI) at a B3LYP/
ma-def2-SVP[39] level of theory using a dispersion correction[40]
and a CPCM model for the protein surface environment (see SI
for details). To this point of the reaction pathway the chiral
center is already formed[38] (Figure 3A).
By overlaying the positions of the pyridine ring of the
catalyst of DFT-derived structures and the crystal structure, one
could argue that the reasons for the missing enantioselectivity
are now obvious. As depicted in Figure 2B the formation of
both enantiomers is possible since both intermediates are not
sterically hindered by surrounding amino acids although the
intermediate leading to the (S) product (Figure 2B, bottom)
seems to undergo more favorable interactions with the protein
(cyclopentenone 1 oxygen to Y124). This should at least induce
a moderate enantioselectivity, which we did not observe.
There is, however, another important detail that has to be
taken into account: After Michael addition of the DMAP 4 to the
enone 2, the resulting positive charge in the intermediate
species (e. g., I2 and I3, Figure 3A) is not primarily located at the
pyridine nitrogen atom, but through mesomerism at the para-
nitrogen atom (Figure S3). As cofactor 4 possesses a six-
membered piperidine at this position, its conformation might
change in order to accommodate a sp2-hybridized iminium
atom. This conformational change propagates through 4
leading to a kinked molecule. Two possible conformations of
the piperidine ring are possible – either the energetically
favored chair conformation[41] (Figure 3C) or the unfavored
(twisted) boat conformation (Figure 3D). The latter is around
3.8 kcal/mol higher in energy for I1 using a truncated cofactor
model.
Interestingly, the piperidine boat conformation of the
catalyst was observed once in a solved crystal structure, namely
in variant S112M Q114A R121A L124Y (PDB ID: 6T2Z, Figure S1).
But only one of the two chains in the asymmetric unit harbors 4
in this conformation. The second chain has electron density for
4 in a piperidine chair conformation. Surprisingly, this variant
had shown the lowest activity of all active variants.
To consider not only the small DFT model, also molecular
dynamics (MD) simulations were carried out to further inves-
tigate reasons for the observed activities of these catalysts. We
used the X-ray structures of the S112F Q114A R121A L124Y and
the S112I Q114A R121A L124Y variants and DFT optimized
structures of biotin-I2 in twisted boat conformation for the S as
well as the R biotin-I2. Altogether, four simulations were carried
out, each lasting 100 ns. While protein backbone as well as
biotin displayed low RMSD values over the whole simulation,
biotin-I2 quickly adopted a chair conformation close to the
protein surface in all structures (Figures S6–S10). Therefore, we
consider the chair conformation to be predominant, which
might limit the efficiency of the artificial cofactor. No prevalent
interactions, in particular hydrogen bonds, of 1 to the protein
could be noticed in any of the simulations (Figure 3E) preferring
the formation of one enantiomer over the other.
According to the presented structures and calculations the
catalytically active site is too shallow to undergo interactions
with 1. As a consequence, 1 approaches I1 in a random fashion,
Figure 2. Crystal structures obtained during the course of catalyst development. Chain A of the corresponding structure is colored, chain B, C and D are in
gray. A) Wt streptavidin (violet; PDB ID: 6T1E) displaying 4, blocked by residues Q114 and R121. Density obtained from the 2mFo  DFc map. B) First and second
rounds of design: S112A, Q114T and R121A (yellow, PDB ID: 6T1G) as well as S112A, Q114A, R121A, L124Y (pink, PDB ID: 6T2Y). Both variants have space at the
original positions of the catalyst, but the catalyst tilted backwards into an inaccessible position. C) Third round of design in which Q114A, R121A and L124Y
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not interacting specifically with the protein leading to a mostly
achiral product. The catalyst might undergo conformational
rearrangements during the course of the reaction to accom-
modate the aforementioned sp2-hybridized iminium atom.
Hence, it should not interact too tightly with the protein, which
might explain the reasons for the different activity levels of the
variants harboring S112I and S122F. The catalytic rate
enhancement of protein with 4 over the rate of sole 4 is most
presumably due to the hydrophobic pocket around the
cofactor, increasing locally the concentration of the substrates
and thus facilitating the formation of I1.
In conclusion, a new artificial cofactor was developed, which
utilizes a known organocatalyst and the biotin-streptavidin
technology to successfully catalyze the Baylis-Hillman reaction.
This protein-cofactor system permits a yield one order of
magnitude higher than the bare artificial cofactor alone. The
system was evolved through repeated cycles of mutagenesis,
activity tests, and structure determination. Hence, all protein
design steps are rationalized. The reaction catalyzed by the
artificial cofactor was further elucidated using DFT calculations
and MD simulations, which identify the shallow binding pocket
of the protein to be the reason for the unexpected outcome.
The binding pocket especially does not allow substrate 1 to be
favored in one position over the other to react with 2 in a
stereoselective fashion.
Our studies clearly demonstrate that careful consideration
of the course of a reaction, if fully understood, including even
small changes, together with a deep knowledge of the
(structural) properties of the target proteins are key to success
in enzyme design. Further, we see that streptavidin, although
used in many cases for the design of artificial enzymes for
reasons described above, might not be a suitable scaffold for
every system. In particular it lacks a deep pocket at the
anchoring site of the catalyst, making it difficult to influence the
stereoselective outcome of a reaction as was the case in our
work.
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Figure 3. Explanation of stereoselective outcome of reaction by using DFT calculated intermediates and the protein crystal structure of streptavidin S112I
Q114A R121A L124Y. A) Proposed reaction mechanism of the Baylis-Hillman reaction. B) Both possible enantiomers of Intermediate 2 (I2) overlaid on the
pyridine ring of catalyst 4. Top: R product (pink), bottom: S product (orange). DFT structure of N-(1-(pyridin-4-yl)piperidin-4-yl)acetamide (turquoise) as catalyst
and intermediate 1 (I1) in the C) chair (yellow) and D) in boat (gold) conformation overlaid on the amide bond. E) Snapshot of molecular dynamics simulation
with biotin-I2 and streptavidin variant S112I Q114A R121A L124Y. Biotin-I2 has a chair conformation, and nitrobenzaldehyde 1 does not undergo any major
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